UPDATE: PTC Therapeutics (PTCT) Initiated Neutral at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Price: $62.84 +0.35%
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 10 | New: 44
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 10 | New: 44
Join SI Premium – FREE
(Updated - October 27, 2020 5:00 PM EDT)
UBS analyst Colin Bristow started PTC Therapeutics (NASDAQ: PTCT) at Neutral, PT $55.00
You May Also Be Interested In
- UBS Reiterates Neutral Rating on Nike (NKE) on Expected Pace of Earnings Recovery
- Tigress Financial Partners Starts Broadcom Limited (AVGO) at Buy
- HSBC Starts Vistra Energy (VST) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
